Home

Vivo Capital VIII, LLC

CIK 1618789 · last filed 2023-12-19

Vivo Capital VIII, LLC is a corporate insider who has filed 10 SEC Form 4 insider transactions across 6 companies since 2017. Across all open-market trades the lifetime net is −$20.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $17.9M across reported positions. The firm reports its address in Palo Alto, CA. 28 SEC filings were submitted jointly with Vivo Capital Fund VIII, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$17.90M

Companies

6

Total Filings

10

Lifetime Open-Market Net

-$20.07M

Filer Profile

Reported Address
192 LYTTON AVENUE
PALO ALTO, CA 94301
Phone
(650) 688-0822
Related Filers
Vivo Capital Fund VIII, L.P. — 28 joint filings, latest 2024-04-03
Vivo Capital Surplus Fund VIII, L.P. — 28 joint filings, latest 2024-04-03
Vivo Opportunity, LLC — 15 joint filings, latest 2024-04-03
Vivo Opportunity Fund, L.P. — 9 joint filings, latest 2021-02-09
Vivo Opportunity Fund Holdings, L.P. — 6 joint filings, latest 2024-04-03
Vivo Panda, LLC — 4 joint filings, latest 2023-11-22
Biohaven Pharmaceutical Holding Co Ltd. — 2 joint filings, latest 2019-02-14
Vivo Capital Fund IX, L.P. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BOLT 10%+ Owner 7,179 $3.95 $28.4K -$559.5K 1 2023-11-20
Terns Pharmaceuticals, Inc. (TERN) Delisted 10%+ Owner 281,223 $52.95 $14.89M $27.50M 1 2022-12-23
IPI Legacy Liquidation Co (IMPL) Delisted 10%+ Owner — $0.24 — $0 1 2021-04-26
Timber Pharmaceuticals, Inc. (BPMX) Delisted 10%+ Owner 26,439 — — -$1.11M 4 2019-06-27
CRNX 10%+ Owner 210,373 $84.95 $17.87M -$46.39M 1 2019-03-25
Nabriva Therapeutics plc (NBRV) Delisted 10%+ Owner 1,977 $1.42 $2.8K $497.9K 1 2017-09-18

Recent Filings

10 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-12-19 — Sell (S) −1,725,000 -$222.4K
2023-11-20 BOLT Sell (S) −602,378 -$559.5K EDGAR
2022-12-23 Terns Pharmaceuticals, Inc. (TERN) Delisted Buy (P) +3,793,100 $27.50M EDGAR
2021-04-26 IPI Legacy Liquidation Co (IMPL) Delisted Other (J) — $0 EDGAR
2019-06-27 Timber Pharmaceuticals, Inc. (BPMX) Delisted Sell (S) −327,870 -$334.4K EDGAR
2019-03-25 CRNX Sell (S) −2,085,000 -$46.39M EDGAR
2018-03-09 Timber Pharmaceuticals, Inc. (BPMX) Delisted Sell (S) −2,000,000 -$720.0K EDGAR
2018-01-31 Timber Pharmaceuticals, Inc. (BPMX) Delisted Conv (C) +4,328,571 $0 EDGAR
2017-11-13 Timber Pharmaceuticals, Inc. (BPMX) Delisted Sell (S) −296,394 -$59.3K EDGAR
2017-09-18 Nabriva Therapeutics plc (NBRV) Delisted Buy (P) +52,631 $497.9K EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.